AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06009406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
Study NCT05390034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ART
Description: Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
Study NCT05390034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
Study NCT05042167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 4 total resistance exercises that target all major muscle groups.
Study NCT04100720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve Transfemoral Tricuspid Valve
Description: The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
Study NCT05820841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-miniCHOP + Acalabrutinib
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks
Study NCT05820841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-miniCHOP
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks
Study NCT04967287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyopiaX
Description: MyopiaX treatment twice a day
Study NCT04967287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia control spectacles
Description: To be used all as prescribed
Study NCT05254925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen oil with 6% Bemotrizinol
Description: Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
Study NCT05254925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen oil vehicle
Description: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
Study NCT05254925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dispersion of 6% BEMT in petrolatum
Description: Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
Study NCT05254925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Petrolatum vehicle
Description: Petrolatum vehicle
Study NCT05316766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation
Description: Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
Study NCT04718402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study NCT04872504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen HPI-enabled EV1000 screen
Description: Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
Study NCT06259604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI
Description: Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
Study NCT06259604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI+kangaroo care
Description: Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
Study NCT05316766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation interactive table
Description: Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
Study NCT04514406 — intervention group
Intervention type: DEVICE
Intervention: APERTO OTW DCB
Description: Drug Coated Balloon Angioplasty
Study NCT05489718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 2 IBI324 of multiple IVT injection
Study NCT05489718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 2 IBI324 of single IVT injection
Study NCT05489718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 1 IBI324 of single IVT injection
Study NCT05489718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 3 IBI324 of single IVT injection
Study NCT05489718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 3 IBI324 of multiple IVT injection
Study NCT04949633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandins
Description: Second cervical ripening lasting a maximum of 24 hours
Study NCT04949633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Induction of labor with oxytocin.
Study NCT04949633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Induction of labor with oxytocin.
Study NCT04116619 — intervention group
Intervention type: OTHER
Intervention: Guided Imagery Laboratory Session
Description: On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol.
Study NCT05538585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral
Study NCT05538585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral
Study NCT05295836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
Study NCT05295836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLYCEROL
Description: Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
Study NCT04825704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
Study NCT04825704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
Study NCT06425406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal cannula
Description: In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
Study NCT04576416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI augmented training and clinical feedback
Description: The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( >10 years of experience) through a web-based review system developed by our group.
Study NCT05693649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Direct Patient Outreach
Description: Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
Study NCT05693649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Colonoscopy Only
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy.
Study NCT05693649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Sequential Choice
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
Study NCT05693649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit-Based Nudge/Text
Description: Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
Study NCT05693649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nudge/Text
Description: Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
Study NCT06249880 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
Study NCT04211649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 days of antibiotherapy
Description: Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
Study NCT05124600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SavvyHealth
Description: Participants will use the new app, SavvyHealth, for 21 days.
Study NCT05799066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swinging Light test
Description: The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
Study NCT05799066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Reality Head-Mounted Display (VR HMD)
Description: A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
Study NCT06351774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
Study NCT06263400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation and follow-up study
Description: In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
Study NCT04345601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
Study NCT04345601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive Care
Description: Patients will receive supportive care per their treating physician
Study NCT04563546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement
Description: A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
Study NCT06233331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level 1 ACU-D1 ointment
Description: ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks.
Study NCT06233331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level 2 ACU-D1 ointment
Description: Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
Study NCT06233331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Level 3 ACU-D1 ointment
Description: Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
Study NCT06233331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vulvar/ Perianal Biopsy
Description: 3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
Study NCT05705648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medium chain triglyceride oil
Description: Medium chain triglyceride oil
Study NCT05705648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower oil
Description: Safflower oil
Study NCT05485987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study NCT05199090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MBL949
Description: subcutaneous injections administered for 14 weeks
Study NCT05199090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator to MLB949
Study NCT06080256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: alirocumab (75 mg every 2 weeks)
Study NCT06080256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20-40mg
Study NCT06080256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20-40mg
Study NCT04826094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Env-C Plasmid DNA
Description: 2 mg per dose. Administered by intramuscular injection.
Study NCT04826094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV Env gp145 C.6980 protein
Description: 100 µg per dose. Administered by intramuscular injection.
Study NCT04826094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rehydragel®
Description: Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
Study NCT04826094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALF43
Description: Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
Study NCT04826094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
Study NCT04826094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: 0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
Study NCT04826094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (TCl)
Description: Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
Study NCT06058676 — intervention group
Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
Study NCT05529420 — intervention group
Intervention type: OTHER
Intervention: measurement of the depth of neuromuscular blockade
Description: time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
Study NCT04797468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX23
Description: administered IV.
Study NCT06442176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
Study NCT05060081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program group
Description: Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
Study NCT05060081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional plank exercise program group
Description: Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
Study NCT06388356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care
Description: Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive.
Study NCT05246943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer and lower limb venous duplex
Description: D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot